Certificate of Analysis (COA) View the laboratory certificate for this product [ View COA ]

V.Med Selank 7000 mcg Nasal Spray

R 700.00
Add to WishlistCompare

V.Med Selank 7000 mcg Nasal Spray

V.Med Selank 7000 mcg Nasal Spray is a research-focused Selank peptide formulation presented in a convenient nasal-spray format.

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro that has been investigated extensively in neuropharmacology and anxiety-related research. Published studies have explored its effects in experimental models involving anxiety-related behaviour, neurotransmitter systems and neurobiological signalling. 

Research has also investigated potential relationships between Selank and the GABAergic system. Experimental molecular research reported that Selank can influence GABA receptor-related binding and proposed allosteric modulation as one possible mechanism underlying observed biological activity. 

Human research has also examined Selank in anxiety-related populations. One randomized clinical study investigated Selank in patients with generalized anxiety disorder and neurasthenia, while other clinical work compared Selank with established anxiolytic treatments. These studies provide research context, but they do not establish that every commercial Selank formulation produces the same effects or that the product should be considered an approved treatment. 

The V.Med Selank 7000 mcg presentation is therefore positioned by Health-Tech as a laboratory research reference product, rather than as a treatment or therapeutic product.

Research Areas

  • Selank peptide research

  • Neuropharmacology

  • GABAergic signalling research

  • Anxiety-related experimental models

  • Neurobiological signalling

  • Cognitive and behavioural research

  • Peptide research

  • Intranasal research models

  • Enkephalin-related research

  • Experimental neuroscience

Research Reference Only: This product is supplied for laboratory research and reference purposes. It is not presented by Health-Tech as a medicine or approved treatment.

Key Features
  • Product: V.Med Selank 7000 mcg
  • Compound: Selank / TP-7
  • Peptide class: Synthetic heptapeptide
  • Format: Nasal spray
  • Label presentation: 7000 mcg
  • Package volume: 10 mL
  • Labelled spray count: 60 sprays
  • Research focus: Neuropharmacology and peptide research
  • Research areas: GABA-related signalling, anxiety models, behavioural research and neurobiology

Specification note: The stated quantity and presentation should be checked against the applicable supplier documentation or COA before using the information for formal batch specifications.

Dosage & Usage

Selank Research Reference

Selank may be of interest in controlled laboratory studies investigating:

Neuropharmacology
Research into peptide-mediated effects on neurological and behavioural pathways.

GABAergic Signalling
Experimental studies have investigated interactions between Selank and GABA receptor systems. 

Anxiety-Related Models
Selank has been investigated in clinical and animal research involving anxiety-related behavioural and physiological measures. 

Enkephalin Research
Experimental studies have investigated Selank's influence on enzymes involved in enkephalin metabolism. 

Behavioural Neuroscience
Animal studies have examined Selank in behavioural models involving stress, exploratory activity and anxiety-related responses. 

FAQ's & Tips

What is Selank?

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro that has been investigated in neuropharmacology and anxiety-related research. 

What is Selank also called?

Selank is commonly referred to as TP-7 in research literature.

What does Selank research focus on?

Research areas include neuropharmacology, anxiety-related models, behavioural neuroscience, GABA-related signalling and enkephalin metabolism.

Has Selank been studied scientifically?

Yes. Selank has been investigated in animal studies, laboratory research and human clinical studies. 

Has Selank been studied in relation to GABA?

Yes. Experimental molecular research has investigated Selank's interaction with GABA receptor-related systems and proposed allosteric modulation as one possible mechanism. 

Has Selank been investigated in humans?

Yes. Published clinical studies have investigated Selank in patients with anxiety-related disorders. 

What is the significance of the nasal-spray format?

The product is supplied in a nasal-spray presentation. Intranasal Selank has also been investigated experimentally, including in animal models. 

Does research establish Selank as an approved treatment?

Research findings should not be interpreted as regulatory approval or proof of therapeutic effectiveness for a particular commercial formulation.

Is this product intended for human consumption?

No. Health-Tech lists this product for laboratory research and reference purposes only.

What is the concentration of this product?

The packaging shown for this V.Med product states 7000 mcg. The complete product specification should be verified against the supplier documentation or COA.

How many sprays are included?

The packaging shown indicates 60 sprays.

What is the bottle volume?

The packaging shown indicates a 10 mL presentation.

Does Health-Tech provide a Selank dosage protocol?

No. Health-Tech's product information is structured around research reference and study protocol notes, rather than human-use dosing instructions.

Is a COA available?

A Certificate of Analysis should be added to the product page once the applicable batch documentation is available.

Research

Selank Peptide Research Overview

Selank is a synthetic heptapeptide derived from the tuftsin-related peptide family. Its amino-acid sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro. Research has examined Selank in both animal and human studies, particularly in relation to anxiety-related behaviour and neurobiological processes. 

GABA-Related Research

One area of interest is Selank's interaction with the GABAergic system.

Experimental research has reported effects on GABA receptor-related binding and proposed that Selank may act as a positive allosteric modulator in particular experimental conditions. These findings have contributed to further investigation of Selank's potential neuropharmacological mechanisms. 

Anxiety-Related Research

Clinical research has investigated Selank in patients with anxiety disorders, including generalized anxiety disorder and related conditions. A 2008 randomized study involving 62 patients compared Selank with medazepam and reported changes in anxiety-related clinical measures. 

A separate clinical comparison involving 60 patients examined Selank alongside phenazepam and evaluated its effects and tolerability in anxiety-related disorders. 

Animal Research

Animal research has investigated both behavioural and receptor-related effects of Selank. Studies comparing different routes of experimental administration have reported changes in behavioural measures and neuroreceptor binding in specific animal models. 

Research has also examined Selank's relationship with enkephalin metabolism, with experimental work reporting inhibition of enzymes involved in enkephalin degradation. 

Reviews